Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis

Laura E. Via, Sangnae Cho, Soohee Hwang, Hyeeun Bang, Seung Kyu Park, Hyung Seok Kang, Doosoo Jeon, Seon Yeong Min, Taegwon Oh, Yeun Kim, Young Mi Kim, Vignesh Rajan, Sharon Y. Wong, Isdore Chola Shamputa, Matthew Carroll, Lisa Goldfeder, Song A. Lee, Steven M. Holland, Seokyong Eum, Hyeyoung Lee & 1 others Clifton E. Barry

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and crossresistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.

Original languageEnglish
Pages (from-to)402-411
Number of pages10
JournalJournal of Clinical Microbiology
Volume48
Issue number2
DOIs
Publication statusPublished - 2010 Feb 1

Fingerprint

Capreomycin
Multidrug-Resistant Tuberculosis
Aminoglycosides
Mycobacterium tuberculosis
Kanamycin
Pharmaceutical Preparations
Streptomycin
Ribosomes
Amikacin
Sputum
Agar
Peptides
Genes

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this

Via, Laura E. ; Cho, Sangnae ; Hwang, Soohee ; Bang, Hyeeun ; Park, Seung Kyu ; Kang, Hyung Seok ; Jeon, Doosoo ; Min, Seon Yeong ; Oh, Taegwon ; Kim, Yeun ; Kim, Young Mi ; Rajan, Vignesh ; Wong, Sharon Y. ; Shamputa, Isdore Chola ; Carroll, Matthew ; Goldfeder, Lisa ; Lee, Song A. ; Holland, Steven M. ; Eum, Seokyong ; Lee, Hyeyoung ; Barry, Clifton E. / Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis. In: Journal of Clinical Microbiology. 2010 ; Vol. 48, No. 2. pp. 402-411.
@article{694555ef07a041468aa4f9f2501aecf4,
title = "Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis",
abstract = "The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34{\%}) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and crossresistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.",
author = "Via, {Laura E.} and Sangnae Cho and Soohee Hwang and Hyeeun Bang and Park, {Seung Kyu} and Kang, {Hyung Seok} and Doosoo Jeon and Min, {Seon Yeong} and Taegwon Oh and Yeun Kim and Kim, {Young Mi} and Vignesh Rajan and Wong, {Sharon Y.} and Shamputa, {Isdore Chola} and Matthew Carroll and Lisa Goldfeder and Lee, {Song A.} and Holland, {Steven M.} and Seokyong Eum and Hyeyoung Lee and Barry, {Clifton E.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1128/JCM.01476-09",
language = "English",
volume = "48",
pages = "402--411",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "2",

}

Via, LE, Cho, S, Hwang, S, Bang, H, Park, SK, Kang, HS, Jeon, D, Min, SY, Oh, T, Kim, Y, Kim, YM, Rajan, V, Wong, SY, Shamputa, IC, Carroll, M, Goldfeder, L, Lee, SA, Holland, SM, Eum, S, Lee, H & Barry, CE 2010, 'Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis', Journal of Clinical Microbiology, vol. 48, no. 2, pp. 402-411. https://doi.org/10.1128/JCM.01476-09

Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis. / Via, Laura E.; Cho, Sangnae; Hwang, Soohee; Bang, Hyeeun; Park, Seung Kyu; Kang, Hyung Seok; Jeon, Doosoo; Min, Seon Yeong; Oh, Taegwon; Kim, Yeun; Kim, Young Mi; Rajan, Vignesh; Wong, Sharon Y.; Shamputa, Isdore Chola; Carroll, Matthew; Goldfeder, Lisa; Lee, Song A.; Holland, Steven M.; Eum, Seokyong; Lee, Hyeyoung; Barry, Clifton E.

In: Journal of Clinical Microbiology, Vol. 48, No. 2, 01.02.2010, p. 402-411.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from south Korean patients with drug-resistant tuberculosis

AU - Via, Laura E.

AU - Cho, Sangnae

AU - Hwang, Soohee

AU - Bang, Hyeeun

AU - Park, Seung Kyu

AU - Kang, Hyung Seok

AU - Jeon, Doosoo

AU - Min, Seon Yeong

AU - Oh, Taegwon

AU - Kim, Yeun

AU - Kim, Young Mi

AU - Rajan, Vignesh

AU - Wong, Sharon Y.

AU - Shamputa, Isdore Chola

AU - Carroll, Matthew

AU - Goldfeder, Lisa

AU - Lee, Song A.

AU - Holland, Steven M.

AU - Eum, Seokyong

AU - Lee, Hyeyoung

AU - Barry, Clifton E.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and crossresistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.

AB - The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and crossresistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.

UR - http://www.scopus.com/inward/record.url?scp=75649111921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649111921&partnerID=8YFLogxK

U2 - 10.1128/JCM.01476-09

DO - 10.1128/JCM.01476-09

M3 - Article

VL - 48

SP - 402

EP - 411

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 2

ER -